Interestingly, the expression levels of HOX genes were not affected by this drug despite the dramatic anti-tumor effect, indicating maybe that MEIS1 could be the shared vulnerability for AML with NPM1c. Similarly, Klossowski and colleagues used the menin inhibitor MI-3454 in a mouse model of NPM1-mutated AML and in patient-derived xenograft models, and showed remarkable anti-leukemic activity, this time, however, downregulating HOX genes and MEIS1 [109]. The gene discussed is NPM1; the disease is acute myeloid leukemia.